SG146681A1 - 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) - Google Patents

4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Info

Publication number
SG146681A1
SG146681A1 SG200807148-2A SG2008071482A SG146681A1 SG 146681 A1 SG146681 A1 SG 146681A1 SG 2008071482 A SG2008071482 A SG 2008071482A SG 146681 A1 SG146681 A1 SG 146681A1
Authority
SG
Singapore
Prior art keywords
cml
treatment
myelogenous leukemia
chronic myelogenous
quinolinecarbonitriles
Prior art date
Application number
SG200807148-2A
Other languages
English (en)
Inventor
Frank Charles Boschelli
Jennifer Michele Golas
Kim Timothy Arndt
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34590192&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG146681(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of SG146681A1 publication Critical patent/SG146681A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Quinoline Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
SG200807148-2A 2003-11-06 2004-11-03 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml) SG146681A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51781903P 2003-11-06 2003-11-06

Publications (1)

Publication Number Publication Date
SG146681A1 true SG146681A1 (en) 2008-10-30

Family

ID=34590192

Family Applications (1)

Application Number Title Priority Date Filing Date
SG200807148-2A SG146681A1 (en) 2003-11-06 2004-11-03 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Country Status (18)

Country Link
US (2) US7417148B2 (pt)
EP (1) EP1680119A1 (pt)
JP (1) JP2007533655A (pt)
KR (1) KR20060118461A (pt)
CN (1) CN1874776A (pt)
AU (1) AU2004289243B2 (pt)
BR (1) BRPI0416289A (pt)
CA (1) CA2543163A1 (pt)
CO (1) CO5690608A2 (pt)
CR (1) CR8350A (pt)
EC (1) ECSP066548A (pt)
IL (1) IL175424A0 (pt)
MX (1) MXPA06004744A (pt)
NO (1) NO20062255L (pt)
RU (1) RU2006113691A (pt)
SG (1) SG146681A1 (pt)
WO (1) WO2005046693A1 (pt)
ZA (1) ZA200603596B (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)
SI1896020T1 (sl) 2005-06-17 2014-11-28 The Board Of Regents Of The University Of Texas System SKI 606 kot inhibitor src kinaze za zdravljenje osteolitičnih lezij
RU2007143434A (ru) * 2005-06-24 2009-07-27 Вайет (Us) 4-анилино-3-хинолинкарбонитрилы, подходящие для лечения раковых заболеваний
WO2008060283A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
WO2008064004A2 (en) * 2006-11-16 2008-05-29 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (aml)
US20080119463A1 (en) * 2006-11-16 2008-05-22 Wyeth 4-Anilino-3-quinolinecarbonitriles for the treatment of acute myelogenous leukemia (AML)
TW200908982A (en) * 2007-06-01 2009-03-01 Wyeth Corp Treatment of imatinib resistant leukemia
WO2013187967A1 (en) 2012-06-15 2013-12-19 Institute For Cancer Research D/B/A The Research Institute Of Fox Case Cancer Center ("Fox Chase Cancer Center") Sensitization of cancer cells to dna damage by inhibiting kinases essential for dna damage checkpoint control
KR102427777B1 (ko) 2012-06-26 2022-08-01 델 마 파마슈티컬스 디안하이드로갈락티톨, 디아세틸디안하이드로갈락티톨, 디브로모둘시톨, 또는 그의 유사체 또는 유도체를 이용하여 유전학적 다형성이 있는 환자에 있어서 티로신-키나아제-억제제 내성 악성종양, ahi1 조절곤란 또는 돌연변이를 치료하는 방법
US9776970B2 (en) 2014-02-20 2017-10-03 Apotex Inc. Bosutinib forms and preparation methods thereof
EP3789027A1 (en) 2015-01-13 2021-03-10 Kyoto University Bosutinib, sunitinib, tivozanib, imatinib, nilotinib, rebastinib or bafetinib for preventing and/or treating amyotrophic lateral sclerosis
US10722484B2 (en) 2016-03-09 2020-07-28 K-Gen, Inc. Methods of cancer treatment
EP3953450A1 (en) 2019-04-09 2022-02-16 Massachusetts Institute Of Technology A micro physiological model for neuronal and muscular diseases and disorders
WO2022053130A1 (en) 2020-09-09 2022-03-17 Sid Alex Group, S.R.O. Antago-mir-155 for treatment of v-src, c-src-tyrosine kinase-induced cancers

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6002008A (en) 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
TWI275390B (en) 2002-04-30 2007-03-11 Wyeth Corp Process for the preparation of 7-substituted-3- quinolinecarbonitriles
US20040229880A1 (en) 2003-02-21 2004-11-18 Wyeth 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury
EP1680119A1 (en) * 2003-11-06 2006-07-19 Wyeth 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (cml)

Also Published As

Publication number Publication date
ECSP066548A (es) 2006-10-17
MXPA06004744A (es) 2006-07-05
US20050101780A1 (en) 2005-05-12
CA2543163A1 (en) 2005-05-26
EP1680119A1 (en) 2006-07-19
CO5690608A2 (es) 2006-10-31
ZA200603596B (en) 2009-12-30
NO20062255L (no) 2006-08-01
US7417148B2 (en) 2008-08-26
IL175424A0 (en) 2008-04-13
JP2007533655A (ja) 2007-11-22
BRPI0416289A (pt) 2007-01-23
KR20060118461A (ko) 2006-11-23
AU2004289243B2 (en) 2010-07-22
US20100029677A1 (en) 2010-02-04
AU2004289243A1 (en) 2005-05-26
WO2005046693A1 (en) 2005-05-26
CN1874776A (zh) 2006-12-06
CR8350A (es) 2006-10-06
US7919625B2 (en) 2011-04-05
RU2006113691A (ru) 2007-12-20

Similar Documents

Publication Publication Date Title
NO20062255L (no) 4-anilino-3-kinolinkarbonitriler for behandling av kronisk myelogenos leukemi (CML)
EP1775289A4 (en) NEW IMIDAZOLIDINE DERIVATIVES
EA200601847A1 (ru) Замещённые метиларил- или гетероариламидные соединения
PT1585739E (pt) Arilciclopropilacetamidas substitu?das como activadores da glucocinase
CY1111310T1 (el) Ενωσεις για την αγωγη μεταβολικων διαταραχων
MXPA05006420A (es) Derivados de pirimidina para el tratamiento de crecimiento celular anormal.
MY139357A (en) Novel benzoimidazole derivatives useful as antiproliferative agents
MXPA04000411A (es) Tiazolidinonas arilo sustituidas y uso de las mismas.
AU2006325931A8 (en) Amine compound and use thereof for medical purposes
IL117875A0 (en) Pharmaceutical compositions for inhibiting th growth of cancers
WO2004071388A3 (en) Medicinal compounds
CA2503451A1 (en) Heterocyclic compounds and antitumor agent comprising the same as effective component
DE60236719D1 (de) Purinderivate als antagonisten an purinergen rezeptoren
HK1085675A1 (en) Anticancer compounds
DK1181299T3 (da) C-2-modificerede erythromycinderivater
BRPI0409959A (pt) uso de derivados de azetidinacarboxamida em terapia
MXPA05008706A (es) 4-[(2, 4- dicloro-5 -metoxifenil) amino]-6 -alcoxi -3- quinolincarbonitrilos para tratamiento de lesiones isquemicas.
WO2005046672A3 (fr) Utilisation d’inhibiteurs de glucosidase pour une therapie de la mucoviscidose
MY136824A (en) Substituted benzoxazinones and uses thereof
TW200714593A (en) Agent for treatment of solid tumor
MY158003A (en) Antibacterial 3',5-disubtituted 2,4'-dihydroproxybiphenyl compounds, derivatives and related methods
MXPA04006041A (es) Antivirales de piridoquinoxalina.
TW200510384A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
WO2008059130A9 (fr) Thionucléosides et applications pharmaceutiques
AP2001002314A0 (en) Substituted benzolactam compounds.